RE:RE:RE:No NewsGbathat wrote: PMN310 stands out from the competition in vitro.
The original Acumen publication cited some anomalies for non-target binding to plaque, and I always thought it was strange that those statements got through the peer review process.
When tested in PMN's lab, it is pretty clear ACU binds significantly to plaque, whereas PMN310 does not. Again, in vitro. The clinic will have the final say.
It is crazy to me that Acumen would have attracted so much investment with this uncertainty in the background. Then again, aducanumab got through FDA approval. It's a desparate world out there- people desperate for a cure, some desperate for a yacht, and some desperate for a cure so they can remember where they docked their yacht. Weird things happen. The truth ultimately sorts it out.
I am excited for the Phase 1b to get going. The anticipation will be epic.
Hoping for a lower dose of PMN-310 to be successful enough that could lead to subcutaneous (injection) dosing of AZ patients in place of intravenous. Makes it easier for patients and presumable less costly. (Big plus) G1945V